보툴리눔톡신(보톡스) 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Botulinum Toxin Market size is expected to reach USD 12.97 Billion in 2034 from USD 6.83 Billion (2025) growing at a CAGR of 7.39% during 2026-2034.

The global botulinum toxin market has experienced strong growth over the past decade. Botulinum toxin is widely used for both cosmetic and medical purposes, such as reducing wrinkles and treating muscle disorders. Increasing interest in non-surgical aesthetic treatments has significantly boosted demand. Rising disposable income and social media influence have also encouraged more consumers to seek cosmetic procedures.

Major drivers include expanding medical applications, such as migraine treatment and muscle spasticity management. Growing awareness about minimally invasive procedures supports market expansion. Technological improvements and new product launches have improved safety and effectiveness. The increasing number of aesthetic clinics and trained professionals further contributes to growth.

Looking ahead, the market is expected to expand as demand for cosmetic procedures continues to rise globally. Emerging markets offer significant opportunities due to changing lifestyles. However, strict regulations and possible side effects may create challenges. Despite this, ongoing product innovation and wider medical use will support steady growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Type A
• Type B

By Application

• Aesthetic (Lateral Canthal Lines, Forehead Lines, Frown Lines/Glabellar, Others)
• Therapeutic (Cervical Dystonia, Muscle Spasm, Strabismus, Hyperhidrosis, Others)

By End-user

• Hospitals
• Ambulatory Surgical Centers
• Dermatology and Speciality Clinics
• Medical Spas
• Beauty/ Wellness Centers
• Others

COMPANIES PROFILED

• Ipsen Biopharmaceuticals Inc, Galderma SA, Allergan Aesthetics an AbbVie company, Taj Pharma Group, Supernus Pharmaceuticals Inc, Merz Therapeutics GmbH, Evolus Inc, Revance Therapeutics Inc, Clarion Medical Technologies Inc, Daewoong Pharmaceutical Co Ltd, Medytox Inc, Sinclair Pharma Ltd, Hugel Inc, Dermax Co Ltd, Daewoong Pharmaceutical Co Ltd
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL BOTULINUM TOXIN MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Type A Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Type B Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BOTULINUM TOXIN MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Aesthetic (Lateral Canthal Lines, Forehead Lines, Frown Lines/Glabellar, Others) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Therapeutic (Cervical Dystonia, Muscle Spasm, Strabismus, Hyperhidrosis, Others) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BOTULINUM TOXIN MARKET: BY END-USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-user
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Ambulatory Surgical Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Dermatology and Speciality Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Medical Spas Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Beauty/ Wellness Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL BOTULINUM TOXIN MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Product
  • 7.2.2 By Application
  • 7.2.3 By End-user
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Product
  • 7.3.2 By Application
  • 7.3.3 By End-user
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Product
  • 7.4.2 By Application
  • 7.4.3 By End-user
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Product
  • 7.5.2 By Application
  • 7.5.3 By End-user
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Product
  • 7.6.2 By Application
  • 7.6.3 By End-user
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL BOTULINUM TOXIN INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Ipsen Biopharmaceuticals Inc
  • 9.2.2 Galderma S.A
  • 9.2.3 Allergan Aesthetics (An AbbVie Company)
  • 9.2.4 Taj Pharma Group
  • 9.2.5 Supernus Pharmaceuticals Inc
  • 9.2.6 Merz Therapeutics GmbH
  • 9.2.7 Evolus Inc
  • 9.2.8 Revance Therapeutics Inc
  • 9.2.9 Clarion Medical Technologies Inc
  • 9.2.10 Daewoong Pharmaceutical Co. Ltd
  • 9.2.11 Medytox Inc
  • 9.2.12 Sinclair Pharma Ltd
  • 9.2.13 Hugel Inc
  • 9.2.14 Dermax Co. Ltd
  • 9.2.15 Daewoong Pharmaceutical Co. Ltd